Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Neurocrine Biosciences Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $4.3, while Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTZ | NBIX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $185.50 |
52-Week Low | $3.63 | $123.10 |
Market Cap | — | $15.77B |
Enterprise Value | — | $15.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $4.04, up 8.46% in the last 24 hours, but technical indicators signal a bearish trend with moving averages and ADX strongly bearish. The stock lacks disclosed financial ratios, suggesting limited fundamental data availability. Recent news highlights ETFs betting against related stocks, indicating negative sentiment in its sector.
The outlook is cautious due to bearish technicals and sparse fundamentals. Risks include market volatility and competitive pressures, with no clear catalysts for upside. Investors should seek updated financial filings for a clearer assessment.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
